Peptide

Larazotide

Also known as

Larazotide acetate · AT-1001 · AT1001 · AT 1001 · INN-202 · GGVLVQPG · H-Gly-Gly-Val-Leu-Val-Gln-Pro-Gly-OH · zonulin antagonist (discussion shorthand) · tight-junction regulator peptide (discussion)

Community talk. May contain inaccuracies. Not medical advice. Not a protocol. Not for human or animal use.

What it is

Oral gut-barrier peptide	Larazotide acetate, AT-1001 or INN-202, is an eight-amino-acid peptide discussed for regulating connections between gut-lining cells. It does not digest gluten.
Different capsule designs	Plain powder, enteric products and N-Ac-Larazotide blends are not established as equivalent. Injection charts are vendor lore, separate from the oral celiac program.

Notes

An oral barrier peptide. Larazotide acetate, also called AT-1001 or INN-202, is a synthetic eight-amino-acid peptide. Tight junctions are the connections between gut-lining cells. Community explainers describe it as helping regulate those connections, rather than digesting gluten or directly rebuilding tissue. Larazotide Acetate (AT-1001): community explainer and dose replies (Community guide · Accessed 2026-09-30) · Delayed-release Larazotide in a porcine model (Animal context · Accessed 2026-09-30)

Form and route change the question. Opened discussions describe capsules. Original notes also describe plain powder capsules, enteric products and N-Ac-Larazotide blends. Those names and equal microgram labels do not establish identical release or activity. Subcutaneous charts in the original record are vendor lore, not the oral celiac development route. Larazotide Acetate (AT-1001): community explainer and dose replies (Community guide · Accessed 2026-09-30)

Source context — Larazotide Acetate (AT-1001): community explainer and dose replies: Educational/promotional tone; advice, not a measured personal course. Mechanism claims do not prove outcomes.

Source context — Delayed-release Larazotide in a porcine model: Pig intestinal-fluid exposure, not human plasma clearance, felt duration or proof of commercial-capsule equivalence.

What people notice

Bloating and energy	Some capsule accounts describe less bloating or more energy; others remain unwell. These comfort reports do not establish healed intestinal damage.
Persistent symptoms	A parent reported no improvement in their child's abdominal pain and nausea on larazotide pills, without amount or duration. Other peptide successes in that thread do not belong to larazotide.

Notes

Larazotide is an oral peptide people discuss for bloating, food-triggered gut symptoms and the idea of a less permeable gut barrier. Some accounts describe relief or more energy; others remain unwell. Its tight-junction story attracts attention, but feeling better does not establish that intestinal damage has healed.

Less bloating, rather than a dramatic rush. A capsule user in r/Sipavibart reported less bloating and planned to return to it after other experiments. That supports a personal comfort report, not their inference that the whole gut was healthier. The original record describes no characteristic stimulant-like “on” sensation. Pemgarda update day 24: Larazotide reply (Personal report · Accessed 2026-09-30)

Energy and food tolerance are separate claims. Long-COVID discussion includes perceived benefit and continued gut problems. A celiac-thread commenter repeats a three-month Larazotide/BPC-157/KPV food-tolerance story heard elsewhere; it is secondhand combination talk, not evidence that Larazotide makes gluten safe. Year on LDN and IVIG: Larazotide experiences (Community discussion · Accessed 2026-09-30) · Larazotide Peptide, anyone currently taking? (Community discussion · Accessed 2026-09-30)

A broader success story includes Larazotide nonresponse. In a broader Long-COVID success thread, a parent said their child's abdominal pain and nausea had not improved after Larazotide pills. The amount and treatment length were unstated. This is an account of persistent symptoms, not evidence that Larazotide caused them, and the thread's other peptide successes cannot be credited to it. Long-COVID peptide discussion: parent reporting Larazotide-pill nonresponse (Personal report · Accessed 2026-09-30)

Source context — Pemgarda update day 24: Larazotide reply: No dose or onset supplied. OP's illness is not a larazotide adverse event; commercial purchase link omitted.

Source context — Year on LDN and IVIG: Larazotide experiences: No amount/form confirmed. Subjective benefit and diagnoses unverified; multiple medications and other interventions.

Source context — Larazotide Peptide, anyone currently taking?: No attributable completed single-agent course; intentions, secondhand reports and opinions are not outcomes.

Source context — Long-COVID peptide discussion: parent reporting Larazotide-pill nonresponse: Second-person caregiver account; amount and duration absent, co-treatment unclear. Do not transfer other compounds' claimed benefits or adverse effects to Larazotide.

Doses people talk about

250 or 500 mcg three times daily	A reply advises these oral per-use amounts, totaling 750 or 1,500 mcg/day. It supplies no personal outcome, and the low-dose chart partly copies trial arms.
One four-times-daily course	One user described 250 then 500 mcg orally four times daily: 1,000 then 2,000 mcg/day. This is one history, not an escalation plan.
Competing wider charts	Saved charts list 0.25–1 mg per dose three times daily; separate blogs list 0.5–2 mg three times daily before meals. These are competing claims, not a measured optimum.

Notes

Oral capsules: 250 or 500 mcg per administration. A PeptideGuide reply mentions each amount three times daily: 750 or 1,500 mcg/day. This is a poster's advice, not a documented personal outcome. The frozen 0.25–0.5 mg pre-meal band partly copies trial doses; it is not independent dose-finding. Larazotide Acetate (AT-1001): community explainer and dose replies (Community guide · Accessed 2026-09-30)

One forum course: 250 then 500 mcg four times daily. godlovesatrier described oral use: 1,000 then 2,000 mcg/day. This is one course, not an escalation recommendation. Larazotide discussion, page 5 (Personal report · Accessed 2026-09-30)

Wider charts remain competing claims. Original protocol notes list 0.25–1 mg per oral dose three times daily (0.75–3 mg/day); separate peptide-blog notes list 0.5–2 mg three times daily (1.5–6 mg/day), 15–30 minutes before meals. Once-daily charts also appear. These are preserved chart claims, not equivalent options or a measured optimum.

Source context — Larazotide discussion, page 5: Repeated posts by one person are one account. Illness, exertion and co-treatment confound it; #100 has unresolved mg units.

Half-life, onset & duration

Felt onset	One account describes improvement after a couple of days; another describes changes during a week with hydrocortisone and other changes. Other users report persistent symptoms.
Felt duration	One user deteriorated over three days off and reported energy returning on restart. This does not establish single-dose coverage or lasting repair after stopping.
Half-life	The record establishes no measured human half-life. Human plasma levels below quantification and pig intestinal-exposure observations cannot supply a consumer clearance interval.

Notes

A couple of days in one account; no useful change in another. AnonymusBosch_ described improvement after a couple of days. swaggiest_sea123 said gut problems persisted after starting in November 2025. Their products, amounts and other treatments differ; neither account defines a reliable onset. Year on LDN and IVIG: Larazotide experiences (Community discussion · Accessed 2026-09-30)

During the first reported week. godlovesatrier described stronger movement and less neck/throat pain during about seven days of use, alongside hydrocortisone and other changes. Larazotide discussion, page 5 (Personal report · Accessed 2026-09-30)

Three days off in one stop/restart story. The same forum author reported deterioration over three days off and renewed energy on restart. This does not measure single-dose coverage. Larazotide discussion, page 5 (Personal report · Accessed 2026-09-30)

Meal-window coverage remains a theory. Original notes describe quieter symptoms while using it and coverage around meals. Opened reports do not establish a dependable wear-off curve or lasting repair after stopping. Continued symptoms after months of use also occur. Year on LDN and IVIG: Larazotide experiences (Community discussion · Accessed 2026-09-30)

No measured human value in these discussions. Capsule frequency is not a clearance measurement. The forum's repeat-dosing discussion supplies no bodily half-life; neither benefit nor relapse tells us when half the peptide has cleared. Larazotide discussion, page 6 (Community discussion · Accessed 2026-09-30)

Animal exposure is not human half-life. Fasted pigs given 1 mg delayed-release oral Larazotide had peak intestinal-fluid concentrations at one hour and detectable amounts over two to four hours. Those are animal exposure observations, not a human duration. Delayed-release Larazotide in a porcine model (Animal context · Accessed 2026-09-30)

Plasma measurements did not yield a half-life. A clinical protocol summarizes oral human plasma concentrations below 0.5 ng/mL quantification. Its repeated-dose table and narrative disagree on 3 versus 4 mg. Neither supports calculating a consumer clearance interval. AT1001 MIS-C 101 clinical research protocol (Official context · Accessed 2026-09-30)

Source context — Year on LDN and IVIG: Larazotide experiences: No amount/form confirmed. Subjective benefit and diagnoses unverified; multiple medications and other interventions.

Source context — Larazotide discussion, page 5: Repeated posts by one person are one account. Illness, exertion and co-treatment confound it; #100 has unresolved mg units.

Source context — Larazotide discussion, page 6: Trial interpretations conflict; participant-number speculation is not adopted. No pharmacokinetic measurements.

Source context — Delayed-release Larazotide in a porcine model: Pig intestinal-fluid exposure, not human plasma clearance, felt duration or proof of commercial-capsule equivalence.

Source context — AT1001 MIS-C 101 clinical research protocol: Background summaries; table/narrative repeated-dose discrepancy (3 vs 4 mg). Not a consumer dosing standard.

Cycles people discuss

Short and prolonged use	One author described about six weeks; another reported nearly two years of helpful use. Neither establishes a standard cycle or long-term safety.
Blocks and restarts	Saved talk includes 8–12-week blocks, continuous maintenance, pauses and restarts around travel, gluten exposure or illness. No dominant on/off calendar is recorded.

Notes

Six weeks versus nearly two years. One forum author described about six weeks total; Henrik reported almost two years of helpful use. Neither establishes long-term safety or a standard cycle. Larazotide discussion, page 5 (Personal report · Accessed 2026-09-30)

Eight to twelve weeks, reassessment and restarts. The frozen community record describes 8–12-week “trial mirror” blocks, continuous maintenance, pauses when symptoms settle or nothing changes, and restarts around travel, accidental gluten or illness. These are different practices, not one validated schedule. No dominant 5-on/2-off or PCT pattern was recorded.

Source context — Larazotide discussion, page 5: Repeated posts by one person are one account. Illness, exertion and co-treatment confound it; #100 has unresolved mg units.

Stacks

BPC-157 and KPV	The marketed gut trio assigns larazotide the barrier role, BPC the repair role and KPV the inflammation role. These are proposed roles, not proven synergy.
Other gut additions	TB-500 blends, glutamine, butyrate, zinc carnosine, apigenin and probiotics appear. Equal-part capsule claims do not establish each component's amount.

Notes

Stack names describe hopes, not proven synergy. Larazotide is assigned the “barrier” job, BPC-157 the “repair” job and KPV the “inflammation” job. The frozen record also includes equal-part BPC-157/TB-500/KPV/Larazotide capsule marketing, glutamine, butyrate, zinc carnosine, apigenin and probiotic combinations. No component doses are established by an equal-part claim; changes cannot be credited to one ingredient. Larazotide Peptide, anyone currently taking? (Community discussion · Accessed 2026-09-30)

Triple “leaky gut” stack: Larazotide + BPC-157 + KPV — heavily marketed on clinics, YouTube explainers, and multi-peptide capsules; 2026 X still calls it the “gut trifecta.” Single-agent credit impossible. [community]

Source context — Larazotide Peptide, anyone currently taking?: No attributable completed single-agent course; intentions, secondhand reports and opinions are not outcomes.

Watch for

Unwanted or persistent symptoms	One responder also reported leg fatigue and stomach upset, with ongoing brain fog. Nausea/cramping, unknown interactions and pregnancy uncertainty remain cautions.
Gluten protection	The celiac trial retained a gluten-free diet. Feeling better does not establish unrestricted-gluten protection, healed tissue or a diagnosis of leaky gut.
More is not established as better	The 0.5 mg three-times-daily celiac trial arm met the primary comparison; 1 and 2 mg did not. Product identity and release remain uncertain in community capsules.

Notes

Relief and unwanted effects can coexist. godlovesatrier also reported leg fatigue and stomach upset. Ongoing brain fog remained. Illness and concurrent treatments complicate attribution. Larazotide discussion, page 5 (Personal report · Accessed 2026-09-30)

A response cannot diagnose “leaky gut.” The Long-COVID exchange jumps from symptom relief to microbial-imbalance explanations. That is the user's interpretation, not a diagnostic test. The old record's nausea/cramping, pregnancy uncertainty and unknown interactions remain cautions, not a complete safety profile. Year on LDN and IVIG: Larazotide experiences (Community discussion · Accessed 2026-09-30)

Gluten-free diet still matters. The celiac trial kept participants on their gluten-free diet. Symptom improvement does not establish unrestricted-gluten protection or healed intestinal tissue. Leffler et al.: persistent celiac symptoms randomized trial (Official context · Accessed 2026-09-30)

The lower-dose trial result has a specific context. In 342 adults with persistent celiac symptoms, 0.5 mg orally three times daily met the primary comparison over 12 weeks; 1 and 2 mg did not. Safety was comparable with placebo. This does not support “more is better” or establish effects of community products. Leffler et al.: persistent celiac symptoms randomized trial (Official context · Accessed 2026-09-30)

Local action is not a safety assurance. Original notes flag product identity, potency and release uncertainties. Injection charts do not settle them. The evidence does not validate every gut, autoimmune, MCAS or long-COVID application discussed online.

Source context — Larazotide discussion, page 5: Repeated posts by one person are one account. Illness, exertion and co-treatment confound it; #100 has unresolved mg units.

Source context — Year on LDN and IVIG: Larazotide experiences: No amount/form confirmed. Subjective benefit and diagnoses unverified; multiple medications and other interventions.

Source context — Leffler et al.: persistent celiac symptoms randomized trial: Abstract-level access; celiac/GFD study, not community-product or general leaky-gut evidence.

Full notes

What Larazotide is

An oral barrier peptide. Larazotide acetate, also called AT-1001 or INN-202, is a synthetic eight-amino-acid peptide. Tight junctions are the connections between gut-lining cells. Community explainers describe it as helping regulate those connections, rather than digesting gluten or directly rebuilding tissue. Community guide Animal context
Form and route change the question. Opened discussions describe capsules. Original notes also describe plain powder capsules, enteric products and N-Ac-Larazotide blends. Those names and equal microgram labels do not establish identical release or activity. Subcutaneous charts in the original record are vendor lore, not the oral celiac development route. Community Community guide

Benefits people seek and how it may feel

Less bloating, rather than a dramatic rush. A capsule user in r/Sipavibart reported less bloating and planned to return to it after other experiments. That supports a personal comfort report, not their inference that the whole gut was healthier. The original record describes no characteristic stimulant-like “on” sensation. Personal report Community
Energy and food tolerance are separate claims. Long-COVID discussion includes perceived benefit and continued gut problems. A celiac-thread commenter repeats a three-month Larazotide/BPC-157/KPV food-tolerance story heard elsewhere; it is secondhand combination talk, not evidence that Larazotide makes gluten safe. Reddit · r/covidlonghaulers Reddit · r/Celiac
A broader success story includes Larazotide nonresponse. In a broader Long-COVID success thread, a parent said their child's abdominal pain and nausea had not improved after Larazotide pills. The amount and treatment length were unstated. This is an account of persistent symptoms, not evidence that Larazotide caused them, and the thread's other peptide successes cannot be credited to it. Personal report

Doses people discuss

Amounts are descriptions, not a regimen. 1 mg equals 1,000 mcg; per-dose and daily totals differ.

Oral capsules: 250 or 500 mcg per administration. A PeptideGuide reply mentions each amount three times daily: 750 or 1,500 mcg/day. This is a poster's advice, not a documented personal outcome. The frozen 0.25–0.5 mg pre-meal band partly copies trial doses; it is not independent dose-finding. Community guide Community
One forum course: 250 then 500 mcg four times daily. godlovesatrier described oral use: 1,000 then 2,000 mcg/day. This is one course, not an escalation recommendation. Personal report
Wider charts remain competing claims. Original protocol notes list 0.25–1 mg per oral dose three times daily (0.75–3 mg/day); separate peptide-blog notes list 0.5–2 mg three times daily (1.5–6 mg/day), 15–30 minutes before meals. Once-daily charts also appear. These are preserved chart claims, not equivalent options or a measured optimum. Community

Half-life

No measured human value in these discussions. Capsule frequency is not a clearance measurement. The forum's repeat-dosing discussion supplies no bodily half-life; neither benefit nor relapse tells us when half the peptide has cleared. Phoenix Rising

Onset: when a change is noticed

A couple of days in one account; no useful change in another. AnonymusBosch_ described improvement after a couple of days. swaggiest_sea123 said gut problems persisted after starting in November 2025. Their products, amounts and other treatments differ; neither account defines a reliable onset. Reddit · r/covidlonghaulers
During the first reported week. godlovesatrier described stronger movement and less neck/throat pain during about seven days of use, alongside hydrocortisone and other changes. Personal report
Four to eight weeks is preserved wellness lore. That window comes from clinic/blog discussion in the original record, not a verified personal timeline. Its separate 4–12-week no-change checkpoint also remains a discussion claim, not an instruction to wait or increase amounts. Community

Duration: how long a benefit lasts

Three days off in one stop/restart story. The same forum author reported deterioration over three days off and renewed energy on restart. This does not measure single-dose coverage. Personal report
Meal-window coverage remains a theory. Original notes describe quieter symptoms while using it and coverage around meals. Opened reports do not establish a dependable wear-off curve or lasting repair after stopping. Continued symptoms after months of use also occur. Community Reddit · r/covidlonghaulers

Cycles and longer use

Six weeks versus nearly two years. One forum author described about six weeks total; Henrik reported almost two years of helpful use. Neither establishes long-term safety or a standard cycle. Personal report
Eight to twelve weeks, reassessment and restarts. The frozen community record describes 8–12-week “trial mirror” blocks, continuous maintenance, pauses when symptoms settle or nothing changes, and restarts around travel, accidental gluten or illness. These are different practices, not one validated schedule. No dominant 5-on/2-off or PCT pattern was recorded. Community

Cautions and limits

Relief and unwanted effects can coexist. godlovesatrier also reported leg fatigue and stomach upset. Ongoing brain fog remained. Illness and concurrent treatments complicate attribution. Personal report
A response cannot diagnose “leaky gut.” The Long-COVID exchange jumps from symptom relief to microbial-imbalance explanations. That is the user's interpretation, not a diagnostic test. The old record's nausea/cramping, pregnancy uncertainty and unknown interactions remain cautions, not a complete safety profile. Reddit · r/covidlonghaulers Community
Gluten-free diet still matters. The celiac trial kept participants on their gluten-free diet. Symptom improvement does not establish unrestricted-gluten protection or healed intestinal tissue. Official context
Local action is not a safety assurance. Original notes flag product identity, potency and release uncertainties. Injection charts do not settle them. The evidence does not validate every gut, autoimmune, MCAS or long-COVID application discussed online. Community

What the community discussion adds

Stack names describe hopes, not proven synergy. Larazotide is assigned the “barrier” job, BPC-157 the “repair” job and KPV the “inflammation” job. The frozen record also includes equal-part BPC-157/TB-500/KPV/Larazotide capsule marketing, glutamine, butyrate, zinc carnosine, apigenin and probiotic combinations. No component doses are established by an equal-part claim; changes cannot be credited to one ingredient. Community Reddit · r/Celiac
Lifestyle cautions are also part of the lore. The original notes flag heavy alcohol and high-dose NSAIDs as counterproductive to barrier goals. That is community reasoning, not a tested Larazotide interaction or proof that removing those exposures makes the peptide work. Community
The Phase 3 story is disputed. Phoenix Rising users debate “not enough resources” versus an inadequate effect; neither reading proves a cure or that nobody can benefit. The sponsor reported an interim reassessment requiring too many additional participants to continue. The study had started; it was not simply never conducted. Phoenix Rising Official context
Experiments overlap with other changes. The capsule responder planned to return after other experiments; the still-symptomatic user had added multiple medications. Their changing courses provide no clean single-agent comparison. Personal report Reddit · r/covidlonghaulers

Supporting research: different questions

The lower-dose trial result has a specific context. In 342 adults with persistent celiac symptoms, 0.5 mg orally three times daily met the primary comparison over 12 weeks; 1 and 2 mg did not. Safety was comparable with placebo. This does not support “more is better” or establish effects of community products. Official context
Animal exposure is not human half-life. Fasted pigs given 1 mg delayed-release oral Larazotide had peak intestinal-fluid concentrations at one hour and detectable amounts over two to four hours. Those are animal exposure observations, not a human duration. Animal context
Plasma measurements did not yield a half-life. A clinical protocol summarizes oral human plasma concentrations below 0.5 ng/mL quantification. Its repeated-dose table and narrative disagree on 3 versus 4 mg. Neither supports calculating a consumer clearance interval. Official context